Skip to Main Content

INFORMATION FOR

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Conditions

Multiple Myeloma

Phase I

What is the purpose of this trial?

The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

  • Trial with
    Yale University
  • Start Date
    02/21/2022
  • End Date
    08/01/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    11/11/2022
  • Study HIC
    #2000028918